Nicotinic acetylcholine receptor silent agonists
OwnerNicole Alana Horenstein, Roger Lee Papke +1inventors
InventorsNicole Alana Horenstein, Roger Lee Papke, Marta Quadri
Life of this patent
Estimating the term…
Loading patent…
OwnerNicole Alana Horenstein, Roger Lee Papke +1inventors
InventorsNicole Alana Horenstein, Roger Lee Papke, Marta Quadri
Estimating the term…
Derivatives of N,N-diethyl-N′-phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.
1-20. (canceled)
A compound having the formula III, or IV:
A pharmaceutical composition comprising a compound having the formula III, or IV:
The pharmaceutical composition of claim 6, wherein said composition is formulated to deliver to a human or animal subject in need thereof, an amount of the compound therapeutically effective in modulating the activity of a nicotinic acetylcholine receptor in the recipient patient, and wherein the therapeutically effective amount is delivered as a single dose or as a series of doses.
A method of modulating the activity of a nicotinic acetylcholine receptor in an animal or human subject by administering to said subject therapeutically effective doses of a silent agonist of the nicotinic acetylcholine receptor and a nicotinic acetylcholine receptor positive allosteric modulator (PAM).
The method of claim 15, wherein the nicotinic acetylcholine receptor positive allosteric modulator (PAM) is a type II PAM.
The method of claim 18, wherein the nicotinic acetylcholine receptor positive allosteric modulator (PAM) is the type II PAM 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea (PNU-120596).
Dependencies are inferred from the claim text.